Psychedelics - What Have You Been Most Surprising About?

4min Snip

00:00

Play full episode

Summary

Transcript

Episode notes

Sally Kohn: I've learned a ton over the past year, just kind of figuring this out on my own. My advice to people is pick a niche and particularly a niche that doesn't have a lot of strong players in it yet. Luckily, with psychedelics, they seem to have this built-in viral component. Once someone has done psychedelics, it's only a matter of time before their friends do it. But being at the right time is very important, too.

Brom Rector is the founder of Empath Ventures, a VC fund that in invests in early-stage psychedelics startups. Prior to founding Empath, Brom sent several years as a portfolio manager and quantitative researcher. Brom joins the show to discuss the current state of the psychedelics industry, the lessons learned founding a VC fund, the differences between psychedelics and cannabis, and a whole lot more. Important Links:

Show Notes:

How Brom became interested in psychedelic investing
Psychedelics and the mental health epidemic
Depoliticising psychedelics
Empath Ventures’ business model
How we can scientifically improve psychedelics
The influence of hippie culture
A contrarian view on Big Pharma
The potential benefits of ibogaine
The differences between cannabis and psychedelics
Do some people not react to psychedelics?
Brom’s thoughts on microdosing
Lessons learned from founding a VC company
The benefits of Rule 506(c)

Books Mentioned:

How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence; by Michael Pollan
Healing Back Pain: The Mind-Body Connection; by John E. Sarno MD